FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013403109> ?p ?o ?g. }

• W2013403109 endingPage "2682" @default.
• W2013403109 startingPage "2682" @default.
• W2013403109 abstract "To evaluate the sensitivity and specificity of transfesrrin dipstick test (Tf) in colorectal cancer (CRC) screening and precancerous lesions screening.Eight hundreds and sixty-one individuals at high-risk for CRC were recruited. Six hundreds and eleven subsequently received the three fecal occult blood tests and colonoscopy with biopsy performed as needed. Fecal samples were obtained on the day before colonoscopy. Tf, immuno fecal occult blood test (IFOBT) and guaiac fecal occult blood test (g-FOBT) were performed simultaneously on the same stool. To minimize false-negative cases, all subjects with negative samples were asked to provide an additional stool specimen for a second test even a third test. If the results were all negative after testing three repeated samples, the subject was considered a true negative. The performance characteristics of Tf for detecting CRC and precancerous lesions were examined and compared to those of IFOBT and the combination of Tf, IFOBT and g-FOBT.A total of six hundreds and eleven subjects met the study criteria including 25 with CRC and 60 with precancerous lesions. Sensitivity for detecting CRC was 92% for Tf and 96% for IFOBT, specificities of Tf and IFOBT were both 72.0% (95% CI: 68.2%-75.5%; χ² = 0.4, P > 0.05); positive likelihood ratios of those were 3.3 (95% CI: 2.8-3.9) and 3.4 (95% CI: 2.9-4.0), respectively. In precancerous lesions, sensitivities for Tf and IFOBT were 50% and 58%, respectively (χ² = 0.8, P > 0.05); specificities of Tf and IFOBT were 71.5% (95% CI: 67.6%-75.1%) and 72.2% (95% CI: 68.4%-75.8%); positive likelihood ratios of those were 1.8 (95% CI: 1.3-2.3) and 2.1 (95% CI: 1.6-2.7), respectively; compared to IFOBT, g-FOBT+ Tf+ IFOBT had a significantly higher positive rate for precancerous lesions (83% vs 58%, respectively; χ² = 9.1, P < 0.05). In patients with CRC and precancerous lesions, the sensitivities of Tf and IFOBT were 62% and 69% (χ² = 0.9, P > 0.05); specificities of those were 74.5% (95% CI: 70.6%-78.1%) and 75.5% (95% CI: 71.6%-79.0%); positive likelihood ratios of those were 2.5 (95% CI: 2.0-3.1) and 2.8 (95% CI: 2.3-3.5). Compared to IFOBT alone, combining g-FOBT, IFOBT and Tf led to significantly increased sensitivity for detecting CRC and cancerous lesions (69% vs 88%, respectively; χ² = 9.0, P < 0.05).Tf dipstick test might be used as an additional tool for CRC and precancerous lesions screening in a high-risk cohort." @default.
• W2013403109 created "2016-06-24" @default.
• W2013403109 creator A5002274704 @default.
• W2013403109 creator A5004118664 @default.
• W2013403109 creator A5007113758 @default.
• W2013403109 creator A5016618002 @default.
• W2013403109 creator A5022401976 @default.
• W2013403109 creator A5022517530 @default.
• W2013403109 creator A5056248574 @default.
• W2013403109 creator A5060427323 @default.
• W2013403109 creator A5083220383 @default.
• W2013403109 date "2012-01-01" @default.
• W2013403109 modified "2023-10-16" @default.
• W2013403109 title "Colorectal cancer screening: Comparison of transferrin and immuno fecal occult blood test" @default.
• W2013403109 cites W109402272 @default.
• W2013403109 cites W140307162 @default.
• W2013403109 cites W172013679 @default.
• W2013403109 cites W1833017948 @default.
• W2013403109 cites W1972071510 @default.
• W2013403109 cites W1973062132 @default.
• W2013403109 cites W1988879680 @default.
• W2013403109 cites W1995463653 @default.
• W2013403109 cites W1998097661 @default.
• W2013403109 cites W2007537740 @default.
• W2013403109 cites W2021362203 @default.
• W2013403109 cites W2021819517 @default.
• W2013403109 cites W2029713316 @default.
• W2013403109 cites W2033285580 @default.
• W2013403109 cites W2040206747 @default.
• W2013403109 cites W2050419748 @default.
• W2013403109 cites W2052672718 @default.
• W2013403109 cites W2060503951 @default.
• W2013403109 cites W2060656209 @default.
• W2013403109 cites W2080308138 @default.
• W2013403109 cites W2091091404 @default.
• W2013403109 cites W2097680546 @default.
• W2013403109 cites W2101995865 @default.
• W2013403109 cites W2104488590 @default.
• W2013403109 cites W2105260966 @default.
• W2013403109 cites W2107036198 @default.
• W2013403109 cites W2113423265 @default.
• W2013403109 cites W2119580931 @default.
• W2013403109 cites W2123968164 @default.
• W2013403109 cites W2125225532 @default.
• W2013403109 cites W2134997723 @default.
• W2013403109 cites W2141131256 @default.
• W2013403109 cites W2147183147 @default.
• W2013403109 cites W2165396052 @default.
• W2013403109 cites W2915602243 @default.
• W2013403109 cites W36627414 @default.
• W2013403109 doi "https://doi.org/10.3748/wjg.v18.i21.2682" @default.
• W2013403109 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3370006" @default.
• W2013403109 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22690078" @default.
• W2013403109 hasPublicationYear "2012" @default.
• W2013403109 type Work @default.
• W2013403109 sameAs 2013403109 @default.
• W2013403109 citedByCount "19" @default.
• W2013403109 countsByYear W20134031092013 @default.
• W2013403109 countsByYear W20134031092014 @default.
• W2013403109 countsByYear W20134031092015 @default.
• W2013403109 countsByYear W20134031092016 @default.
• W2013403109 countsByYear W20134031092017 @default.
• W2013403109 countsByYear W20134031092018 @default.
• W2013403109 countsByYear W20134031092019 @default.
• W2013403109 countsByYear W20134031092021 @default.
• W2013403109 countsByYear W20134031092022 @default.
• W2013403109 countsByYear W20134031092023 @default.
• W2013403109 crossrefType "journal-article" @default.
• W2013403109 hasAuthorship W2013403109A5002274704 @default.
• W2013403109 hasAuthorship W2013403109A5004118664 @default.
• W2013403109 hasAuthorship W2013403109A5007113758 @default.
• W2013403109 hasAuthorship W2013403109A5016618002 @default.
• W2013403109 hasAuthorship W2013403109A5022401976 @default.
• W2013403109 hasAuthorship W2013403109A5022517530 @default.
• W2013403109 hasAuthorship W2013403109A5056248574 @default.
• W2013403109 hasAuthorship W2013403109A5060427323 @default.
• W2013403109 hasAuthorship W2013403109A5083220383 @default.
• W2013403109 hasBestOaLocation W20134031091 @default.
• W2013403109 hasConcept C121608353 @default.
• W2013403109 hasConcept C126322002 @default.
• W2013403109 hasConcept C151730666 @default.
• W2013403109 hasConcept C2778435480 @default.
• W2013403109 hasConcept C2779158730 @default.
• W2013403109 hasConcept C526805850 @default.
• W2013403109 hasConcept C61716771 @default.
• W2013403109 hasConcept C71924100 @default.
• W2013403109 hasConcept C86803240 @default.
• W2013403109 hasConcept C90924648 @default.
• W2013403109 hasConceptScore W2013403109C121608353 @default.
• W2013403109 hasConceptScore W2013403109C126322002 @default.
• W2013403109 hasConceptScore W2013403109C151730666 @default.
• W2013403109 hasConceptScore W2013403109C2778435480 @default.
• W2013403109 hasConceptScore W2013403109C2779158730 @default.
• W2013403109 hasConceptScore W2013403109C526805850 @default.
• W2013403109 hasConceptScore W2013403109C61716771 @default.
• W2013403109 hasConceptScore W2013403109C71924100 @default.
• W2013403109 hasConceptScore W2013403109C86803240 @default.
• W2013403109 hasConceptScore W2013403109C90924648 @default.

• next